ES2129515T3 - Administracion topica de toremifeno y sus metabolitos. - Google Patents

Administracion topica de toremifeno y sus metabolitos.

Info

Publication number
ES2129515T3
ES2129515T3 ES93906654T ES93906654T ES2129515T3 ES 2129515 T3 ES2129515 T3 ES 2129515T3 ES 93906654 T ES93906654 T ES 93906654T ES 93906654 T ES93906654 T ES 93906654T ES 2129515 T3 ES2129515 T3 ES 2129515T3
Authority
ES
Spain
Prior art keywords
pct
metabolites
date oct
toremifene
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93906654T
Other languages
English (en)
Inventor
Michael William Degregorio
Kauko Oiva Antero Kurkela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orion Oyj
Original Assignee
Orion Yhtyma Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Yhtyma Oy filed Critical Orion Yhtyma Oy
Application granted granted Critical
Publication of ES2129515T3 publication Critical patent/ES2129515T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

SE PRESENTAN PREPARACIONES TOPICAS QUE CONTIENEN COMO INGREDIENTE ACTIVO TOREMIFENO O UNO DE SUS METABOLITOS N-DIMETILTOREMIFENO O 4HIDROXI-TOREMIFENO O SUS SALES NO TOXICAS FARMACOLOGICAMENTE ACEPTABLES QUE SON UTILES PARA EL TRATAMIENTO DE CANCERES LOCALIZADOS EN LA PIEL O A CORTA DISTANCIA DE LA PIEL TALES COMO LAS LESIONES METASTASICAS DEL CANCER DE PULMON. TAMBIEN PUEDEN UTILIZARSE COMO COADYUVANTES EN LA TERAPIA DEL CANCER DE PULMON Y PARA INVERTIR LA RESISTENCIA MULTIDROGA DE LAS CELULAS CANCERIGENAS A LAS DROGAS CITOTOXICAS. DICHAS PREPARACIONES TOPICAS SON DE PARTICULAR INTERES EN EL TRATAMIENTO DEL MELANOMA, LINFOMA, SARCOMA DE KAPOSI Y MICOSIS FUNGOIDES.
ES93906654T 1992-04-03 1993-03-25 Administracion topica de toremifeno y sus metabolitos. Expired - Lifetime ES2129515T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929207437A GB9207437D0 (en) 1992-04-03 1992-04-03 Topical administration of toremifene and its metabolites

Publications (1)

Publication Number Publication Date
ES2129515T3 true ES2129515T3 (es) 1999-06-16

Family

ID=10713495

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93906654T Expired - Lifetime ES2129515T3 (es) 1992-04-03 1993-03-25 Administracion topica de toremifeno y sus metabolitos.

Country Status (20)

Country Link
US (1) US5605700A (es)
EP (1) EP0633774B1 (es)
JP (1) JPH07505375A (es)
AT (1) ATE176757T1 (es)
AU (1) AU674307B2 (es)
CA (1) CA2133429C (es)
DE (1) DE69323549T2 (es)
DK (1) DK0633774T3 (es)
EE (1) EE02972B1 (es)
ES (1) ES2129515T3 (es)
FI (1) FI944597A0 (es)
GB (1) GB9207437D0 (es)
GR (1) GR3029819T3 (es)
HU (1) HU221813B1 (es)
IL (1) IL104986A (es)
NO (1) NO309225B1 (es)
NZ (2) NZ249889A (es)
RU (1) RU2140785C1 (es)
WO (1) WO1993019746A1 (es)
ZA (1) ZA931760B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
DE69435137D1 (de) * 1993-05-13 2008-10-16 Poniard Pharmaceuticals Inc Prävention und behandlung von pathologien, die mit einer abnormalen proliferationglatter muskelzellen verbunden sind
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
GB9609171D0 (en) * 1996-05-02 1996-07-03 Orion Yhtymae Oy Antioxidant compounds
US6764690B2 (en) * 1996-05-29 2004-07-20 Delsitech Oy Dissolvable oxides for biological applications
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US7846919B2 (en) * 1998-02-10 2010-12-07 Dermex Pharmaceuticals, Llc Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions
US6248752B1 (en) * 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6413535B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
EA003466B1 (ru) * 1998-05-07 2003-06-26 Те Юниверсити Оф Теннесси Рисерч Корпорейшн Способ химиопрофилактики рака предстательной железы
US20030130316A1 (en) * 2000-03-20 2003-07-10 Steiner Mitchell S. Method for chemoprevention of prostate cancer
US20040176470A1 (en) * 1998-05-07 2004-09-09 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2000009101A2 (en) * 1998-08-11 2000-02-24 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) * 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
DE10042411A1 (de) * 2000-08-30 2002-03-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Exemestan
EP1330251A4 (en) * 2000-10-06 2006-03-15 Intarcia Therapeutics Inc POLYTHERAPY FOR THE TREATMENT OF OESTROGENIC SENSITIVE DISEASE
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
CN100548283C (zh) 2001-11-29 2009-10-14 Gtx公司 雄激素剥夺引起的骨质疏松症的预防和治疗
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US7371773B2 (en) * 2003-02-04 2008-05-13 Kabushiki Kaisha Yakult Honsha Breast cancer resistance protein (BCRP) inhibitor
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
JP2007529426A (ja) 2004-03-12 2007-10-25 エントレメッド インコーポレイテッド 抗血管新生薬
MD2765G2 (ro) * 2004-12-06 2006-01-31 МЕРЕУЦЭ Ион Unguent pentru tratamentul afectiunilor oncologice ale glandei mamare
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
JP2009530388A (ja) 2006-03-20 2009-08-27 エントレメッド インコーポレイテッド ２−メトキシエストラジオールの疾患修飾性抗関節炎活性
CN101448490A (zh) 2006-05-22 2009-06-03 霍尔莫斯医疗有限公司 治疗慢性非细菌性前列腺炎的选择性雌激素受体调节剂或者芳香酶抑制剂
US20080176255A1 (en) * 2007-01-23 2008-07-24 Edward Sobek Mold detection composition and methods
WO2008099059A1 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Method for the preparation of therapeutically valuable triphenylbutene derivatives
WO2008099060A2 (en) 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
PL3202420T3 (pl) * 2008-12-11 2020-07-13 Besins Healthcare Luxembourg Sarl Transdermalne kompozycje farmaceutyczne zawierające SERM
WO2011085303A1 (en) * 2010-01-11 2011-07-14 Gtx, Inc. Method for hormone ablative therapy induced osteoporosis
WO2011137376A2 (en) * 2010-04-30 2011-11-03 University Of Rochester Compounds for anti-fungal treatment
US9321712B2 (en) 2012-10-19 2016-04-26 Fermion Oy Process for the preparation of ospemifene
WO2014124504A1 (en) * 2013-02-13 2014-08-21 Katholieke Universiteit Leuven Ku Leuven Research & Development Compositions and methods for treating biofilms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI67538C (fi) * 1982-05-27 1985-04-10 Farmos Oy Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten
FI77839C (fi) * 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
GB2126576B (en) * 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
JPS60130512A (ja) * 1983-12-15 1985-07-12 Nitto Electric Ind Co Ltd 皮膚疾患治療用テ−プ製剤
FR2558373B1 (fr) * 1984-01-20 1987-07-03 Mauvais Jarvis Pierre Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
GB8604528D0 (en) * 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
DE3634016A1 (de) * 1986-04-17 1987-10-29 Lohmann Gmbh & Co Kg Flaechenfoermiges therapeutisches system, verfahren zu seiner herstellung und seine verwendung
JPS63230641A (ja) * 1987-03-19 1988-09-27 Shiseido Co Ltd 経皮吸収促進剤及びこれを含有する皮膚外用製剤
IE62095B1 (en) * 1988-03-29 1994-12-14 Univ Florida Pharmaceutical formulations for parenteral use
US4990538A (en) * 1989-08-23 1991-02-05 Harris Adrian L Use of toremifene and its metabolites for the reversal of multidrug resistance of cancer cells against cytotoxic drugs
US5189212A (en) * 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity

Also Published As

Publication number Publication date
CA2133429A1 (en) 1993-10-14
EP0633774B1 (en) 1999-02-17
FI944597A (fi) 1994-10-03
FI944597A0 (fi) 1994-10-03
NO309225B1 (no) 2001-01-02
AU674307B2 (en) 1996-12-19
DE69323549T2 (de) 1999-07-29
GR3029819T3 (en) 1999-06-30
DE69323549D1 (de) 1999-03-25
JPH07505375A (ja) 1995-06-15
NZ280219A (en) 1997-05-26
EE02972B1 (et) 1997-04-15
WO1993019746A1 (en) 1993-10-14
HU9402830D0 (en) 1994-12-28
US5605700A (en) 1997-02-25
IL104986A0 (en) 1993-07-08
ATE176757T1 (de) 1999-03-15
CA2133429C (en) 2004-08-31
NO943669L (no) 1994-09-30
ZA931760B (en) 1993-09-30
GB9207437D0 (en) 1992-05-20
NZ249889A (en) 1996-02-27
DK0633774T3 (da) 1999-09-20
RU2140785C1 (ru) 1999-11-10
NO943669D0 (no) 1994-09-30
AU3754493A (en) 1993-11-08
HUT70845A (en) 1995-11-28
IL104986A (en) 1997-08-14
EP0633774A1 (en) 1995-01-18
HU221813B1 (hu) 2003-01-28

Similar Documents

Publication Publication Date Title
ES2129515T3 (es) Administracion topica de toremifeno y sus metabolitos.
ITMI911149A1 (it) Composizioni farmaceutiche in forma di schiuma per somministrazione intravaginale, cutanea e orale
SG64325A1 (en) Thermoplastic elasomeric copolymers and hair and skin care compositions containing the same
IL101145A0 (en) Pharmaceutical compositions containing synergistic combinations of nucleoside derivatives
SG52692A1 (en) Silicone grafted thermoplastic elastomeric copolymers and hair and skin care compositions containing the same
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
TR27984A (tr) Silikon asili termoplastik elastomerik kopolimerler ve bunlari iceren sac ve cilt bakimi bilesimleri.
IT9020025A0 (it) Dispositivo per la somministrazione di sostanze medicamentose in polvere
TR199500832A2 (tr) Benzimidazol türevleri ve bunlarin medikal terapide kullanimi ve bunlari iceren farmasötik formülasyonlar.
AR043071A1 (es) Uso de macrolidos para el tratamiento del cancer y degeneracion macular y una composicion farmaceutica
DE69215999D1 (de) Therapeutische Mittel für die Behandlungder Resistenz gegen Arzneimittel bei Krebs
GR3022033T3 (en) Transdermal system with stepwise drug release, and its use in local or systemic cosmetic administration
ATE107853T1 (de) Orales, melatonin enthaltendes arzneimittel.
NO970178L (no) Terpenoidderivater (sarcodictyiner) som er nyttige som antitumormidler
ITRM910155A0 (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l'impiego degli stessi.
IT1254452B (it) N-ossidi ed n,n'-diossidi di 3-(piperazin-1-il)-propan-1,2-dioli

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 633774

Country of ref document: ES